Health China

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. e-TC: Development and pilot testing of an online psychosocial intervention to reduce anxiety and depression in testicular cancer survivors Smith A, Heiniger L, Butow P, Gimison P, Klein B, Wootten A, Abbott J, Price M, McJannett M, Trna B, Stockler M, Gurney H, Olver I. International PsychoOncology Meeting January, 2015
2. Linking of Guidelines with Educational Tools and Other Resources International Collaboration Enhances Development and Dissemination of Innovative Digital Cancer Guidelines December, 2014
3. Multidisciplinary Care Using Teleoncology models in Models of Care in Teleoncology: Innovation in Rural Cancer Service Delivery Prog 2014 UICC World Cancer Congess, 171 December, 2014
4. Post Testicular Cancer Treatment Cognition – Clearing the Fog Clinical Oncology Society of Australia, Annual Scientific Meeting December, 2014
5. Lung Cancer: Butt out or screen? Clinical Oncology Society of Australia, Annual Scientific Meeting December, 2014
6. UICC Members Regional Meeting – Convening the Cancer Community From Western Pacific Prog 2014 UICC World Cancer Congess December, 2014
7. The clinical and research implications of peace as part of spiritual wellbeing assessment in quality of life in cancer Whitford, H. S., & Olver, I. N. 2014 UICC World Cancer Congress, Melbourne, Australia December, 2014
8. Cancer Control and Quality: the Australian experience Prog 2014 UICC World Cancer Congess, 271 December, 2014
9. Preserving Hope and Saying Goodbye in Gynaecologic Oncology International Gynaecologic Cancer Society 15th Biennial Meeting Melbourne, Australia November, 2014
10. Psychometric properties of the Functional Assessment of Chronic Illness Therapy – Spiritual Well-Being, Expanded Whitford, H. S., Jones, S. B. W., & Olver, I. N 21st International Society for Quality of Life Research (ISOQOL) Annual Conference October, 2014
11. Are Guidelines Old Technology? Panel Debate 11th Guidelines International Network Conference, Melbourne August, 2014
12. The importance of spiritual wellbeing domains in quality of life assessment: replicating and extending evidence of clinical utility. Olver, I. N., & Whitford, H. S. Medical Oncology Group of Australia (MOGA) 2014 Annual Scientific Meeting, Sydney, Australia August, 2014
13. Investigating the clinical relevance of spiritual wellbeing domains in quality of life assessment Olver, I. N., & Whitford, H. W. International Symposium on Supportive Care in Cancer (MASCC/ISOO) June, 2014
14. Spiritual wellbeing’s clinical utility in quality of life assessment Olver, I. N., & Whitford, H. W. E-reference published for the American Society of Clinical Oncology (ASCO) 50th Annual Meeting: Science and Society, Chicago May, 2014
15. Advances in Cancer Treatment RACMA Scientific Program, Sydney. April, 2014
16. Public Health and Genomic Cancer Medicine Genomic Cancer Medicine Workshop The Kinghorn Cancer Centre, Sydney March, 2014
17. The Impact of Global Warming and Ozone Depletion on Skin Cancer Rates iDEA14 Doctors for the Environment Australia Conference. Melbourne March, 2014
18. Debunking the Myths World Cancer Day Event International Atomic Energy Agency, Vienna February, 2014
19. Using an Option grid to facilitate informed participation in cervical cancer screening in rural primary care practice, Tamil Nadu, India: A Phase I study Trevina LJ. Isaac R, Olver I, Finkel M. Society for Medical Decision-Making, Singapore, 2014. January, 2014
20. How should we manage conflicts of interest in biomedicine? Mayes C, Lipworth W, Kerridge I, Stewart C, Komesaroff P, Olver I Australasian Association of Bioethics and Health Law. Conference, Perth 2014 January, 2014
21. Convergent validity of the newly proposed four-component structure of the Functional Assessment of Chronic Illness – Spiritual Wellbeing, Expanded Whitford HS, Olver IN International Society of Psycho-oncology, Brussels January, 2014
22. E-TC development and pilot testing of a web-based intervention to reduce anxiety and depression in survivors of testicular cancer. Heiniger L, Butow P, Olver I, Gimison P, Smith AB, Klein B, Wotten A, Abbott J-A, Price MA, McJannet M, Tran B, Stockler M, Gurney H. Asia Pac J Clin Oncol 2014, 10 (Suppl 8):abs 88, 102 January, 2014
23. Cervical cancer information needs of disadvantaged rural women in Tamil Nadu, India: Designing a patient-centred interactive VoiceSite accessed via mobile phone. Trevina LJ. Isaac R, Olver I, Finkel M Society for Medical Decision-Making, Singapore, 2014. January, 2014
24. Convergent validity of the newly proposed four-component structure of the Functional Assessment of Chronic Illness – Spiritual Wellbeing Expanded Whitford HS, Olver IN International Psychooncology Society Conference 2014 January, 2014
25. Exploring the Impact of Chronic Disease and Consequences for the Most Vulnerable and Socially Disadvantaged Social Determinants of Health Conference December, 2013
26. Best Practice and Improving Services 5th Annual Cancer Centres Symposium, Melbourne. December, 2013
27. The Big Debate- Three Minutes to Change the World by 2025. World Cancer Leaders Summit Cape Town. November, 2013
28. Personalised medicine – invited public lecture. HRMI Workshop on Personalised Medicine HRMI Newcastle. November, 2013
29. Plenary III Challenges and Solutions for Updating guidelines G-I-N Conference, San Francisco. August, 2013
30. Viruses and Cancer Cancer Council WA Update series. Perth August, 2013
31. Improving the patient journey through e-resources: wikis, models for clinicians, the iHeard website and more Health Informatics Conference 2013 Adelaide. July, 2013
32. Assessing the use of wiki based clinical practice guidelines for lung cancer. Olver IN Proc MASCC Berlin Abs 264 Jun 2013. June, 2013
33. Diagnostic Dilemmas During And After Treatment General Practitioner Conference and Exhibtion. Sydney. May, 2013
34. Developing the Cancer Council Australia Wiki Platform Australian Patient Safety Foundation Meeting, Sydney. April, 2013
35. Corporate Social Responsibility Helping Ensure a Safe Well-rounded Workplace Safety in Action 2013: SIA National Safety Convention Melbourne March, 2013
36. Surviving Cancer: The psycho-social impact on the family Eliott J, Olver I Australasian Society for Behavioural Health in Medicine 8th Annual Scientific Conference Christchurch February, 2013
37. Alcohol, Women and Cancer – New Understandings. Healthed, Annual Women’s Health update February, 2013
38. Assessing the use of wiki based clinical practice guidelines for lung cancer. Olver I, von Dincklage J, Garrett A, Holliday L, Vuletich C MASCC/ISOO International Symposium on Supportive Care in Cancer January, 2013
39. Involving consumers in intervention design; lesson learnt from the development of www.countrysupport.com.au Gunn K, Turnbull D, McWha L, Davies M, Bidargaddi N, Olver I. 12 National Rural Health Conference January, 2013
40. How to successfully connect rural cancer patients and their supporters with supportive care: a culturally acceptable, online South Australian example. Gunn KM, Turnbull D, McWha L, Davies M, Bidargaddi N, Olver I. MASCC/ISOO International Symposium on Supportive Care in Cancer. Berlin Germany 2013: Abs 478 January, 2013
41. P008 Keeping cancer guidelines current using a wiki approach Olver IN BMJ Qual Saf 2013, 22:A4. January, 2013
42. Wiki-based treatment guidelines for lung cancer Olver IN 15th World Conf on Lung Cancer Sydney 2013. January, 2013
43. Investigating symptoms of Lung Cancer – an evidence-based guide for general practitioners Mazza D, Chakraborty S, Jones K, Olver I, Zorbas H GP12, Gold Coast Convention and Exhibition Centre October, 2012
44. The Cancer Research Funding Landscape National Cancer Research Summit, Cancer Research Leadership Forum, Sydney. September, 2012
45. The relationship between privacy law and cancer research McCabe Centre for Law and Cancer. Using the law effectively for cancer control. Montreal, Canada. August, 2012
46. Should advance care directives be part of routine practice in Australia? Medical Oncology Group of Australia Annual Scientific Meeting Brisbane. August, 2012
47. Exploring life and Death Decision-Making MOGA ASM Brisbane. Asia Pacific J Clin Oncol. 2012 (Suppl 2) August, 2012
48. The role of individual patient, social and treatment variables in the psychosocial outcomes of cancer patients Tasmanian Haematology, Immunology and Neoplasia Group (THING) 36th Weekend Scientific Meeting, Strachan, Tasmania April, 2012
49. Nullifying Nausea Tasmanian Haematology, Immunology and Neoplasia Group (THING) 36th Weekend Scientific Meeting, Strachan, Tasmania April, 2012
50. FCTC Articles 11 and 13 and the tobacco industry response to plain packaging Olver I 15th World Conference on Tobacco or Health March, 2012
51. patients’ perceptions of nausea: is it clusters of symptoms? Olver I, Eliott JA, Koczwara B Support Care Cancer 2012, 20(Suppl 1): S79 January, 2012
52. Nausea still the poor relation in antiemetic therapy? The symptom cluster triad of nausea, vomiting, and appetite loss: individual and combined effects on quality of life during cancer treatment. Pirri C, Bayliss E, Trotter J, Olver IN, Katris P, Drummond P, Bennett R. Asia-Pac J Clin Oncol 2012, 8(Suppl 3): 125. January, 2012
53. Lower levels of serum testosterone, quality of life, and treatment for testicular cancer: a prospective cohort study. Fournier M, Grimison P, Stockler L, Whitford H, Toner G, Thomson D, Davis I, Hanning F, Singhal N, Underhill C, Clingan P, McDonald A, Boland A, Olver I Asia Pac J Clin Oncol 2012, 8(Suppl 1): Abs 104, 30 January, 2012
54. Chemotherapy-Cognition study update Olver I Asia Pac J Clin Oncol. 2012, 8(Suppl 1):Abs 26, 27. January, 2012
55. Surprising results regarding MASCC members’ beliefs about spiritual care Ramondetta L, Sun C, Konishi T, Baioder L, Ripamonti C, Olver I, Johnson J, Surbone A Support Care Cancer 2012, 20(Suppl 1): S136-S137 January, 2012
56. Perspectives on complementary and alternative medicines (CAM). Olver I Asia-Pac J Clin Oncol 2012, 8(Suppl 3): 292. January, 2012
57. Suffering in Cancer – conceptualization, assessment and interventions. A systematic literature review Best M, Aldridge L, Butow P, Price M, Zorbas H, Webster F, Olver I. Asia-Pac J Clin Oncol 2012, 8(Suppl 3): 272 January, 2012
58. Men with cancer using complementary and alternative medicine (CAM): variation in significant other’s involvement. Klafke N, Eliott J, Olver I, Wittert G Asia-Pac J Clin Oncol 2012, 8(Suppl 3): 237. January, 2012
59. Lower levels of serum testosterone, quality of life, and treatment for testicular cancer: a prospective cohort study Olver IN, Fournier M, Stockler M, Whitford H, Toner G, Thomson D, Davis I, Hanning F, Singhal N, Underhill C, Clingan P, McDonald A, Boland A, Grimison P. Asia-Pac J Clin Oncol 2012, 8(Suppl 3): 214. January, 2012
60. More than just a pain in the neck – improving our understanding and responses tot eh supportive care needs of patients with head and neck cancer Turner J, Burmeister B, Carrington C, Dong S, Doyle M, Fraser A, Olver I Asia-Pac J Clin Oncol 2012, 8(Suppl 3): 149. January, 2012
61. Connecting rural cancer patients and their families and carers with psychosocial support: the development of a website using a participatory action research framework and behavioural change theory Gunn KM, Turnbull D, McWha L, Davies M, Olver I Asia-Pac J Clin Oncol 2012, 8(Suppl 3): 143. January, 2012
62. Losing your marble(s): A cross-sectional study of psychosocial outcomes in Australian testicular cancer survivors. Smith AB, King M, Butow P, Luckett T, Grimison P, Toner G, Stockler M, Hovey E, Stubbs J, Olver I. Asia-Pac J Clin Oncol 2012, 8(Suppl 3): 131-132. January, 2012
63. Aspirin for whom and for preventing which disease? COSA ASM Perth. Asia-Pacific Journal of Clinical Oncology 7 (Suppl 4). November, 2011
64. What are you hoping for? The role of families in end-of-life decision-making Australasian Association of Bioethics and Health Law July, 2011
65. Submitting Manuscripts for Publication and Consideration: Key Issues and Lessons Learned MASCC Symposium Athens Support Care Cancer 19 (Suppl 2) Abs 873 S361. June, 2011
66. Phase 2 trial of aprepitant on days 1-7 for patients with germ cell tumours having cisplatin on days 1-5. I. Olver, P. Grimison, M. Chatfield, M.R. Stockler, G. Toner, V. Gebski, R.A. Harrup, C. Underhill, G. Kichenadasse, N. Singhal, A.L. Boland, A. McDonald, D.B. Thomson MASCC/ISOO International Symposium on Supportive Care June, 2011
67. Nutrition the next target in cancer prevention Olver I Science of Nutrition in medicine and Healthcare May 2011, 62. May, 2011
68. Nutrition the next target in cancer prevention International Conference on the Science of Nutrition and healthcare. Sydney. May, 2011
69. Lung cancer search filters: connecting to the evidence. Tieman JJ, Damarell R, Currow D, Olver I Asia Pac J Clin Oncol 2011,7(Suppl 4)Abs 361, 164 January, 2011
70. A comparison of data quality and practicality of online versus postal questionnaires in a sample of testicular cancer survivors Smith AB, King MT, Butow PN, Olver IN. Asia Pac J Clin Oncol 2011, 7(suppl 4) Abs 019, 75 January, 2011
71. Phase II trial of aprepitant on days 1 to 7 for patients with germ cell tumours having cisplatin on days 1 to 5. Thomson D, Grimison P, Chatfiels M, Stockler M, Toner G, Gebski V, Harrup R, Boland A, McDonald A, Olver I. Asia-Pac J Clin Oncol 2011, 7(Suppl 3): 6 January, 2011
72. Tele oncology clinics in rural Queensland: A cost-effective cancer care model. Thaker D, Sabesian S, Van Houts B, Bryett A, Olver I Asia Pac J Clin Oncol 2011. 7(Suppl 3): 38 January, 2011
73. Issues in funding phase III trials. Tieman J, Damarell R, Currow D, Olver I Asia Pac J Clin Oncol 2011, 7(Suppl 4): Abs 362, 164-5 January, 2011
74. Qualitative study of survivorship issues in the families of patients with cancer Olver IN, Eliott JA European Journal of Cancer - EUR J CANCER 01/2011; 47. Abs 3028 DOI:10.1016/S0959-8049(11)71101-7 January, 2011
75. COSA’s Role in CAMS 36th Annual Scientific Meeting COSA Gold Coast November, 2010
76. Family and surviving cancer International Union for Cancer Control (UICC). (Eliott, J.) August 2010, Shenzhen, China August, 2010
77. Women and stress: Psychoneuroimmunology and the role of vitamin supplementation. Oliver-Baxter JM, Whitford HS, Turnbull D, Olver IN, Chalmers AH International Congress of Applied Psychology (ICAP) July, 2010
78. Hope, life and death: What can dying cancer patients and their families do with hope? IPOS 12th World Congress of Psycho-oncology June 2010, Quebec June, 2010
79. Peace, meaning, and faith: isolating which dimensions of spiritual wellbeing are most integral to improving quality of life and coping in patients with new cancer diagnoses Whitford H, Olver I. IPOS 12th World Congress of Psycho-oncology May, 2010
80. The impact of expectations on experience: further exploring the influence of anxiety and cancer coping styles on chemotherapy-naive patients’ expected side effects. Whitford H, Olver I IPOS 12th World Congress of Psycho-oncology May, 2010
81. A study of what dimensions of spiritual wellbeing impact on quality of life in patients with cancer, and what can impact on spiritual wellbeing. Olver IN, Whitford HS 10th Behavioural Research in Cancer Control (BRCC) Conference April, 2010
82. What makes a good DNR decision: dying patients talk about doctors, patients and decision-making Behavioural Research in Cancer Control. April 2010, Melbourne, Australia. April, 2010
83. The psychoneuroimmunology of breast cancer patients: a pilot study Oliver-Baxter JM, Whitford HS, Olver IN, Turnbull D, Chalmers AH 36th Clinical Oncological Society of Australia’s (COSA) Annual Scientific Meeting, Gold Coast, Queensland, Australia November, 2009
84. Intercessory prayer improves spiritual wellbeing in a randomised controlled trial in patients with cancer Olver IN, Whitford HS. 36th Clinical Oncological Society of Australia’s (COSA) Annual Scientific Meeting November, 2009
85. Intercessory prayer improves spiritual wellbeing in a randomised controlled trial in patients with cancer. Olver IN, Whitford HS 15th European Cancer Organisation September, 2009
86. The psychoneuroimmunology of breast cancer patients: a pilot study Oliver-Baxter JM, Whitford HS, Olver IN, Turnbull D, Chalmers AH University of Adelaide Postgraduate Expo, Adelaide, Australia September, 2009
87. Using the media for cancer messages Medical Oncology Group of Australia ASM, Canberra Asia Pacific Journal of Clinical Oncology 5 August, 2009
88. The multidimensionality of spiritual wellbeing: Meaning, peace, and faith and their association with quality of life and coping in an oncological population. Whitford, H. S. & Olver, I. N. 3rd Australian Conference on Spirituality and Health. Adelaide, Australia July, 2009
89. The multidimensionality of spiritual wellbeing: Meaning, peace, and faith and their association with quality of life and coping in an oncological population. Whitford, H. S. & Olver, I. N. Multinational Association of Supportive Care in Cancer (MASCC) International Symposium June, 2009
90. Study Endpoints MASCC Meeting Rome June, 2009
91. Prayer Improves Spiritual Wellbeing in a randomized controlled trial in patients with cancer Olver IN, Whitford H. Asia Pacific J Clin Oncol 2009, 5(2): Abs 145, A172. January, 2009
92. Moving beyond focused on individual characteristics and coping with cancer: a grounded theory approach Knott V, Turnbull D, Olver I, Winefield A Asia Pacific J Clin Oncol 2009, 5(2): Abs 415, A248. January, 2009
93. The psychoneuroimmunology of breast cancer patients: a pilot study. Oliver JM, Whitford H, Turnbull D, Olver IN, Chalmers AH Asia Pacific J Clin Oncol 2009, 5(2): Abs 314, A223. January, 2009
94. The multidimensionality of Spiritual wellbeing: Meaning peace and faith and their association with quality of life and coping in an oncological population. Whitford H, Olver I Support Care Cancer 2009, 17 Abs 23-318, 1023 January, 2009
95. What makes a good Do-Not-Resuscitate Decision? Dying cancer patients talk about patients, doctors, and DNR decision-making. Eliott J, Olver IN 7th Interdisciplinary Conference on Communications, Medicine, & Ethics January, 2009
96. Future options for cancer management 5th State Cancer Conference Western Australia. October, 2008
97. Leadership in oncology or quick tips on how to change the world Medical Oncology Group of Australia Annual Scientific Meeting. August, 2008
98. The cancer treatment journey as recorded by patients using unstructured journals Olver I, Eliott J, Long L, McKinnon M, Rumsby G Asia-Pacific Journal of Clinical Oncology 2008, 4 (Suppl 2): Abs 408. COSA. January, 2008
99. The psychological impact of treatment for cancer as recorded by patients using unstructured journals Olver I, Eliott J, Long L, McKinnon M, Rumsby G Supp Care Cancer 2008, 16 (6): 733 Abs 20-209. January, 2008
100. Patients’ use of humour in discussing sensitive end-of-life issues Olver IN, Eliott J Psycho-Oncology 2008, 17(6) Suppl: S31 Abs 8L-1 January, 2008
101. Monoclonal Antibodies for Advanced Breast cancer 1St Kuala Lumpur international Breast and Colorectal Conference, Kuala Lumpur. August, 2007
102. The Use of Targeted Therapies. Can we afford it? 1St Kuala Lumpur international Breast and Colorectal Conference, Kuala Lumpur. August, 2007
103. Oncology 2027 Australian Medical Students Association Annual Meeting July, 2007
104. Novel Therapies in Cancer Cancer Council WA public Lecture Series Perth. July, 2007
105. Telehealth Tumour Teams: diagnostics and management 9th National Rural Health Conference, Albury, NSW. March, 2007
106. The impact of Australia Asia Pacific Clinical Oncology Research Development (ACORD) on research productivity of participants according to region of origin. Koczwara B, Ackland S, Esterman A, Marine F, Stockler M, Olver I. Proc Am Soc Clin Oncol 2007: 43: Abs 17074. January, 2007
107. A randomized controlled trial of a written form versus an interactive multimedia CD-ROM to provide information prior to consent to chemotherapy. Olver I N, Whitford S Asia Pacific J Clin Oncol 2007, 3 (Suppl 1) Abs A8 January, 2007
108. Using an interactive CD-ROM to gain informed consent for chemotherapy: Attempting to improve patient anxiety and depression during treatment. Olver IN, Whitford HS Proc Am Soc Clin Oncol 2007, 43: Abs 17071 January, 2007
109. A randomized trial of written information versus an interactive multimedia CD-ROM for improving informed consent to chemotherapy. Olver IN, Whitford HS Eur J Cancer 2007, 5 (4): 143 Abs 1105 January, 2007
110. The Role of Spirituality in Quality of Life Clinical Oncological Society of Australia ASM Melbourne November, 2006
111. New Technologies and Challenges Australian Health Insurance Association Conference, Sydney. November, 2006
112. The Future of Cancer in Australia: The Cancer Council Australia Perspective Clinical Oncological Society of Australia ASM Melbourne November, 2006
113. Improving the chemotherapy consent process: Longitudinal assessment of patient recall Hedayati H, Whitford H, Olver I 8th World Congress of Psychooncology October, 2006
114. Improving informed consent to chemotherapy: Written information versus an interactive CD-ROM Olver I, Whitford H 8th World Congress of Psychooncology October, 2006
115. Spirituality as a core domain in the assessment of quality of life in oncology: An Australian perspective Whitford H, Olver I, & Peterson M 8th World Congress of Psychooncology October, 2006
116. Spirituality as a core domain in the assessment of quality of life in an Australian oncology population Olver I, Whitford H, Peterson M Medical Oncology Group of Australia (MOGA) Annual Scientific Meeting August, 2006
117. What Multidisciplinary Treatment Means to Me Australian Lung Cancer Conference 2006, Palm Cove Cairns. July, 2006
118. Lung Cancer and The Cancer Council Australia Australian Lung Cancer Conference 2006, Palm Cove Cairns. July, 2006
119. State of the Art in Clinical Practice: Targeting the future in tumour treatment International Society of Oncology Practice Pharmacy invited presentations April, 2006
120. The Ethics of Resource Allocation- What Price? International Society of Oncology Practice Pharmacy invited presentations April, 2006
121. Spirituality as a core domain in the assessment of quality of life in an Australian Oncology Population Olver IN, Whitford H, Peterson M Int Med J 2006, 36(Suppl 4): A158 January, 2006
122. Satisfaction and productivity of participants in the Australia Asia Pacific Clinical Oncology Research Development (ACORD) Workshop Koczwara B, Esterman A, Marine F, Olver I, Stockler M Int Med J 2006, 36(Suppl 4): A155. January, 2006
123. Feasibility study on the Mammosite in early stage breast cancer. Borg M, Bochner M, Butters J, Davies C, van Doorn T, Farshid G, Iasella J, Kolias J, Kotasek D, Gill G, Lim A, Nguyen K, Olver I, Rush G, Whitford H, Yeoh E RACR Ann Scientific Meeting 2006 January, 2006
124. The meanings of “hope” to patients with cancer, nearing the end of their lives. Olver IN, Eliott JA J Clin Oncol 2006, 24 (18s): 693s. January, 2006
125. Maintaining guideline currency in an ever-changing world: a sustainable model for the future Alison Evans, Ornella Care, Helen Zorbas, Ian Olver Asia Pacific Journal of Clinical Oncology 2006, 2(Suppl 2): Abs 648. January, 2006
126. Complementary and alternative medicine: A discourse analytic study of cancer patient’s talk. Olver I, Eliott JA, Kealey CP. Asia Pacific Journal of Clinical Oncology 2006, 2(Suppl 2): A169. January, 2006
127. The patient in the family: A discursive analytic study of dying patients’ (and their family’s) talk on the Do-not-resuscitate decision Eliott JA, Olver IN Psycho-Oncology 2006, 15(Supp. 2), Abs 547 January, 2006
128. The meanings of ‘Hope’ to patients living and dying with cancer Olver IN, Eliott JA Psycho-Oncology 2006, 15(Supp. 2), Abs 827 January, 2006
129. Using Complementary and Alternative Medicine: A discourse analytic study of cancer patients’ talk Eliott JA, Olver IN Psycho-Oncology 2006, 15(Supp. 2), Abs 276 January, 2006
130. Hoping is better than hope: A discursive analysis of dying cancer patients’ talk. Eliott J, Olver I Aust J Psychology, 2006, 58 (Suppl), (Abs) p. 27 January, 2006
131. Analysis of the speech of dying patients with cancer on end-of-life decision-making. Eliott J, Olver I. Aust J Psychology, 2006, 58 (Suppl), (Abs) pp. 26-7 January, 2006
132. Improving informed consent to chemotherapy: Written information versus and interactive CD-ROM Olver S, Olver I, Whitford H Clinical Oncological Society of Australia Inc., (COSA) Scientific Meeting November, 2005
133. Feasibility study on the Mammosite in early stage breast cancer. Borg M, Bochner M, Butters J, Davies C, van Doorn T, Farshid G, Iasielle J, Kollias J, Kotasek D, Gill G, Lim A, Nguyen K, Olver I, Rush G, Whitford H, Yeoh E Annual Scientific Meeting of the Royal Australian and New Zealand College of Radiologists October, 2005
134. The change in cancer patients perceptions as ‘End of Life’ approaches Indian Co-operative Oncology Network meeting. Vellore, India. September, 2005
135. Chemotherapy –Induced Nausea and Vomiting. Is the current regimen sufficient? Malaysian Oncology Society Meeting, Kuala Lumpur September, 2005
136. Optimising Antiemetic Therapy for CINV Scientific Congress and Annual Meeting, Taiwan Society of Cancer Palliative Medicine, Taipei September, 2005
137. Death or Dollars? The ethics of resource allocation International Society of Oncology Pharmacy Practice meeting, Adelaide. September, 2005
138. The change in cancer patients perceptions as ‘End if Life’ approaches Medical staff, Ludhiana, India. September, 2005
139. An overview of medical oncology/pharmaceutical interactions Medical Oncology Group of Australia, Hobart. August, 2005
140. Treatment of Australian Indigenous Patients Medical Oncology Group of Australia, Hobart. August, 2005
141. Cancer service delivery in regional and rural Australia – the problems and prospects 8th National Rural Health Conference, Alice Springs March, 2005
142. Analysing Interviews about End-Of-Life decision Making with Patients With Cancer Who Were Dying Olver I, Eliott J Support Care Cancer 2005, 13: 473 Abs 24-179 January, 2005
143. Changes in cancer patients’ perceptions of do-not-resuscitate orders as end of life (*EOL) approaches Olver IN, Eliott JA Proc Am Soc Clin Oncol 2005, 23 (16S): 747s Abs 8072. January, 2005
144. Multicentre phase II study of gemcitabine and carboplatin combination therapy for patients with metastatic carcinoma of unknown primary site: final results. Pittman KB, Olver IN, Karapetis CS, Kotasek D, Price TJ, Patterson WK, Keefe DM< Koczwara B, Parnis FX, Greer D Proc am Soc Clin Oncol 2005, 23 (16S): 764s Abs 8142 January, 2005
145. Selective Internal Radiation Therapy (SIRT) plus systemic chemotherapy with Irinotecan. A phase I dose escalation study Goldstein D, van Hazel G, Pavlakis N, Olver I Proc Am Soc Clin Oncol 2005, 23 (16S): 296s Abs 3701. January, 2005
146. A pilot study of Celecoxib with Docetaxel/Radiation and Consolidation Docetaxel/Cisplatin in Inoperable Stage IIIa and IIIb Non Small Cell Lung Cancer. Olver IN, Borg M, Pittman K, Karapetis C, Jurisevic C Lung Cancer 2005, 49 (suppl 2); S392 Abs 52 January, 2005
147. The implication of dying patients’ speech on determining appropriateness of cardiopulmonary resuscitation and do-not-resuscitate orders Eliott J, Olver I Proc 3rd International Conference on Communication, Medicine and Ethics Sydney 2005, 29 January, 2005
148. Advances in Management of Emesis Supportive Therapies at Clinical Oncological Society of Australia ASM, Canberra. November, 2004
149. New Treatment Strategies Cancer Council ACT and Consumer Alliance Network, Consumer Forum on Cancer, Canberra November, 2004
150. Spirituality in Cancer: An Holistic Approach Cancer Council ACT and Consumer Alliance Network, Consumer Forum on Cancer, Canberra November, 2004
151. Breakthroughs in Antiemetic Treatment NA October, 2004
152. Optimising Anti-Emetic therapy for Chemotherapy Induced Nausea and Vomiting Launch of Aprepitant, Kuala Lumpar July, 2004
153. Recent Advances in the Treatment of CINV: NK1 Receptor Antagonists Launch of Aprepitant, Kuala Lumpar July, 2004
154. IressaTM-The First EGFR in the Treatment of Lung Cancer Symposium of the Hong Kong Cancer Therapy Society, Hong Kong. May, 2004
155. Steward for the Australia Cancer Anaemia Survey (ACAS) Group. Tara Seshadri, H. Miles Prince, Paul Coughlin, Philip. James, Gary Richardson, Boris Chern, Peter. Briggs, John Norman, Ian Olver, Chris Karapetis, John Proc Haem Soc Aust NZ 2004 January, 2004
156. Analysis of the speech of dying patients with cancer on end-of-life decision making Olver IN, Eliott JA Proc Am Soc Clin Oncol 2004, 22: 782s January, 2004
157. Analysis of the speech of dying patients with cancer on do not resuscitate orders. Olver IN, Eliott JA Prog COSA 2004 31: 64 January, 2004
158. Outcomes and health status of patients undergoing usual care for highly emetogenic chemotherapy Olver IN Prog COSA 2004, 31: 140 January, 2004
159. The use of videophones to enhance palliative care outreach nursing in remote areas. Olver I, Brooksbank M, Champion N, Keely J, Healey T. 7th Australian Palliative Care Conference September, 2003
160. The negative consequences of regarding individual autonomy as the prime consideration in the treatment decisions made by patients with cancer Olver, I.N., Whitford, H.S., & Eliott, J.A Medical Oncology Group of Australia Annual Scientific Conference August, 2003
161. Optimising antiemetic therapy for CINV National Cancer Institute and Launch Meeting of Aprepitant, Singapore. August, 2003
162. End of Life Issues Pewsitters and Prophets, National Conference of Diocesan Social Issues Committees, Adelaide February, 2003
163. Multi-national phase III trials of aprepitant for the prevention of CINV: Translation and linguistic validation of an emesis diary and patient questionnaire into 22 languages. Nadjar A, Martin AR, Giroudet C, Lewis S, Conway K, Lindley C, Olver I. Proc Am Soc Clin Oncol 2003, 22: Abs 3158, 786. January, 2003
164. Exploring telemedicine to extend palliative care outreach in remote communities Olver IN, Brooksbank M, Champion N, Keeley J, Healey T. Proc Am Soc Clin Oncol 2003, 22: Abs 2957, 735. January, 2003
165. Phase II study of gemcitabine and carboplatin as combination therapy for patients with metastatic carcinoma of unknown primary site (CUP): Preliminary results Pittman KB, Olver IN, Karapetis CS, Kotasek D, Price TJ, Patterson WK, Keefe DM, Koczwara B, Parnis FX, Moldovan S Proc Am Soc Clin Oncol 2003, 22: Abs 3074, 765. January, 2003
166. Rational and emotional persons: the ideal and the real in patients’ decision-making at the end of life. Eliott J, Olver I Prog First Interdisciplinary Conference on Communication, Medicine and Ethics. 2003, 47 January, 2003
167. Improved survival at the cost of neurotoxicity in primary CNS lymphoma (PCNSL). Long-term follow-up of a phase 2 multicentre combined modality study O’Brien PC, Roos DR, Pratt G, Liew K, Barton M, Poulsen M, Olver I, Trotter G. ECCO 2003 Vol 1 no 5, S214 Abs 712 January, 2003
168. Exploring telemedicine to extend palliative care outreach in remote areas. Olver I, Brooksbank M, Champion N, Keeley J, Healey T Prog COSA 2003, 30: 49 January, 2003
169. Optimism and survival in lung cancer patients: is ‘being positive’ just an additional burden Schofield P, Ball D, Smith JG, Borland R, O’Brien P, Davis S, Olver I, Ryan G, Joseph D Prog COSA 2003, 30: 69 January, 2003
170. Pharmacokinetics of E21R, a GM-CSF antagonist,, in patients with end stage solid tumours Somogyi AA, Foster DJR, Olver I , Hercus T, Wigley P. Ann Conf Aust Pharmaceutical Science Assoc Melb Dec 2002 December, 2002
171. NSCLC Second Line Treatment Philippine Society of Medical Oncology 16th Annual Convention Manila, Philippines. October, 2002
172. Can we improve outcome in patients with small cell lung cancer in patients who achieve complete remissions Philippine Society of Medical Oncology 16th Annual Convention Manila, Philippines. October, 2002
173. The rational use of antiemetics Malaysian Oncology Society Annual Meeting Kuala Lumpar September, 2002
174. Managing metastatic breast cancer Malaysian Oncology Society Annual Meeting Kuala Lumpar September, 2002
175. Antiemetics –NK1’s Medical Oncology Group Australia and Faculty of Radiation Oncology National Conference 2002 August, 2002
176. Workshop: Writing a Research Funding Proposal Medical Oncology Group Australia and Faculty of Radiation Oncology National Conference 2002 August, 2002
177. The New Wonder Drug – Glivec Royal Australasian College of Surgeons Annual Scientific Congress, Adelaide. May, 2002
178. Multi-disciplinary Cancer Care Royal Australasian College of Surgeons Annual Scientific Congress, Adelaide. May, 2002
179. Motivational interviewing for smoking cessation among patients with cancer: randomised controlled trial Olver IN, Wakefield M, Rosenfeld E, Whitford H. Proc Am Soc Clin Oncol 2002, 21: Abs 1524, 382a. January, 2002
180. Predicting from a smoking cessation trial which patients with cancer are likely to quit smoking Olver IN, Wakefield M, Rosenfeld E, Whitford H. Ann Oncol 2002, 13 (suppl 5) 125 Abs 459P. January, 2002
181. A randomised trial in cancer patients of motivational interviewing foe smoking cessation. Olver I, Wakefield M, Rosenfeld E, Whitford H. Proc COSA 2002, 29, 74 Abs 36 January, 2002
182. Delivery of Health Services to Rural and Remote Australia Clinical Oncological Society of Australia Annual Scientific Meeting, Brisbane. November, 2001
183. Chemotherapy for Breast Cancer Normah Hospital, Kuching, Sarawak, Malaysia July, 2001
184. Charter of Paris Against Cancer SA Trade Mission, Malaysia in Kuala Lumpar and Penang July, 2001
185. The Role of Chemotherapy in the Management of Cancer Normah Hospital, Kuching, Sarawak, Malaysia July, 2001
186. Exploring Collaborations in Cancer Management, Education and Research SA Trade Mission, Malaysia in Kuala Lumpar and Penang July, 2001
187. Characteristics of smokers with cancer recruited to a smoking cessation trial Wakefield M, Rosenfeld, E, Whitford H, Olver I, & Roberts L 1st National Tobacco Control Conference. June, 2001
188. Teleoncology Rural Health Conference Canberra. March, 2001
189. Characteristics of smokers with cancer recruited to a smoking cessation prevention trial. Wakefield M, Rosenfeld E, Whitford H, Olver I Proc COSA, 2001, 28: Abs 111, 100 January, 2001
190. Ambulatory carboplatin and oral etoposide for prostate cancer Olver I, Keefe D, Myers M Proc COSA, 2001, 28: Abs 18, 53 January, 2001
191. Delivery of Health Services to Rural and Remote Australia Olver I Proc COSA 2001, 28: Abs 5, 47. January, 2001
192. Is Hope Out There? The Empirico-Realist Approach to Hope. Critical Issues in Qualitative Research Eliott JA, Olver IN Association for Qualitative Research Abs 56, July 2001 January, 2001
193. Ambulatory Carboplatin and Oral Etoposide for Metastatic Hormone Resistant Prostate Cancer Olver IN, Keefe DA, Myers M Proc Am Soc Clin Oncol 2001, 20: Abs January, 2001
194. New treatment options The Australian Prostate Cancer Collaboration Annual Meeting, Adelaide SA. November, 2000
195. Paclitaxel in Gynaecologic Malignancies Satellite Symposium, Gynaecology Oncology Congress, Istanbul, Turkey September, 2000
196. Chemotherapy in the Treatment of Unresectable Non Small Cell Lung Cancer Oncology Update, Agra India August, 2000
197. Cancer Patients’ Perceptions of DNR Orders Hematology, Oncology and Bone Marrow Transplantation Grand Rounds, University of Iowa Cancer Centre. May, 2000
198. End of life issues Australian Health and Welfare Chaplains Association Annual Conference, Adelaide February, 2000
199. The influence of pretreatment optimism on outcome in patients given radical radiotherapy for non-small cell lung cancer. Ball D, Borland R, Smith J, Bishop J, O’Brien P, Davis S, Olver I, Walker Q, Ryan G, Joseph D. Proc 9th World Conf Lung Cancer 2000 January, 2000
200. Autonomy and end-of-life decision making. Olver IN, Eliott J Psycho-Oncol 2000, 9, 5 (Suppl): Abs 147, S37. January, 2000
201. Daily versus weekly administration of cisplatin in combined chemotherapy. Marcu L, van Doorn T, Olver I 14th AIP Congress, Adelaide January, 2000
202. E21R: a GM-CSF antagonist with potential as an anticancer agent Wigley P, Olver I, Bardy P, Donadieu J, Lopez A, Verma M Proc 11th NCI-EORTC-AACR Symposium on New Drugs 2000. January, 2000
203. The consequences of hope: Constructions of hope and the experience of cancer. Eliott J, Olver IN. Psycho-Oncol 2000, 9, 5 (suppl): Abs 245, S62 January, 2000
204. Autonomy and Do Not Resuscitate Decision Making. Olver IN, Eliott JA Proc Australian Bioethics Association 2000 Conference January, 2000
205. Patient Understanding of written consent to chemotherapy Aherns C, Denson L, Moar K, Olver I Psycho-Oncol 2000, 9, 5 (suppl): abs 290, S73 January, 2000
206. ‘Do not resuscitate’ vs ‘Good palliative care’: A qualitative study of cancer patients’ speech. Eliott J, Olver I Proc COSA 2000, Abs 118 January, 2000
207. The family impact on individual DNR decision-making: a qualitative study. Elliot J Olver I. Proc COSA 2000, Abs 149. January, 2000
208. Smoking Cessation with people with cancer – a qualitative thematic analysis Rosenfeld E, Wakefield M, Olver I, Cooke R. Proc COSA 2000, Abs 57 January, 2000
209. Communication and cancer: shared experiences from a Darwin/Adelaide teleoncology link Olver I, Selva-Nayagam S, Healey T, Fisher D. Proc COSA 2000, Abs 10 January, 2000
210. A phase I study of the GM-CSF antagonist E21R Olver I, Vadas M, Lopez A, Taylor A, Brown M, To B, Cole J, Rawling T, Verma M, Wigley P Proc COSA 2000, Abs 75 January, 2000
211. A phase I study of the GM-CSF antagonist E21R Olver IN, Vadas MA, Lopez A, Keefe DM,, Taylor AE, Brown MP, To LB, Cole J, Rawling M, Wigley P. Proc Am Soc Clin Oncol 2000, 19: 475a January, 2000
212. Paclitaxel combinations in solid tumours satellite symposium to National Turkish Cancer Congress, Antalya, Turkey. April, 1999
213. An Australian multi-centre phase III study of accelerated fraction radiotherapy with or without concurrent carboplatin in inoperable non small cell lung cancer. Ball D, Bishop J, Smith J, O’Brien P, Davis S, Ryan G, Olver I, Toner G, Walker Q, Joseph D. Royal ANZ College of Radiologist Ann Scientific Meeting January, 1999
214. Cancer Patient Perceptions of Do Not Resuscitate Orders. Olver I, Elliot J, Blake-Mortimer J. Proc Am Soc Clin Oncol, 1999, 18: Abs 2328 January, 1999
215. A phase II of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary. Olver I, Parnis F, Kotasek D, Norman J, Taylor A, Russell J, Patterson K, Keefe D, Marafioti T Proc COSA 1999, 26: Abs 14 January, 1999
216. Community perceptions of cancer risk Wakefield M, Olver I, Roberts L 2nd World Conference for Cancer Organisations January, 1999
217. Community beliefs about cancer treatment and care in South Australia Olver I 2nd World Conference for Cancer Organisations January, 1999
218. End of life decision making: the perspectives of patients with cancer Olver I, Eliott J, Blake-Mortimer J. Proc COSA 1999, 26: Abs 2 January, 1999
219. Cancer patient perceptions of Do Not Resuscitate (DNR) orders Joint Annual Scientific Meeting of the Northern Territory Branches of the Royal Australasian College of Physicians and the Australasian Faculty of Public Health Medicine – Darwin NT November, 1998
220. Matters of Life and Death, a Hypothetical 33rd Annual Convention of Australian Humanist Societies. April, 1998
221. Conquering the Crab: Impact of chemotherapy on immune function Tasmanian Haematology Immunology and Neoplastic Group” 22nd annual meeting, Bronte Park, Tasmania. March, 1998
222. A Phase I Trial with Pharmacokinetics of paclitaxel and altretamine for ovarian cancer relapsing following cisplatin IN Olver, M Davy, L Webster, M Egorin, D Luftner, S-H Park Annals of Oncol, 1998, 9: Abst 327P. January, 1998
223. Interluekin-3 Fails to Reduce Thrombocytopenia After Carboplatin & Etoposide Chemotherapy: A Randomized, Placebo-Controlled Trial GC Toner, IN Olver, G Richardson, D Bell, S Ackland, D Ransom, J Grygiel, JF Bishop. Proc Am Soc Clin Oncol 1998, 17: Abst 327. January, 1998
224. Phase II Trial of Taxol (T) and Oral Etoposide (E) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). MJ Boyer, J Zalcberg, SJ Clarke, MJ Millward, IN Olver, P Mitchell, G Richardson, D Goldstein. Proc Am Soc Clin Oncol. 1998, 17: Abst 1840. January, 1998
225. Australian Randomised Phase III Trial of Concurrent Carboplatin and Twice Daily Radiotherapy (RT) in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) JF Bishop, D Ball, JG Smith, PO O’Brien, S David, G Ryan, G Toner, D Joseph, Q Walker, I Olver, E Crennan Proc Am Soc Clin Oncol 1998, 17: Abst 1785. January, 1998
226. Paclitaxel and Altretamine for Ovarian Cancer Relapsing Following Cisplatin. IN Olver, M Davy, C Burgeois Proc Am Soc Clin Oncol. 1998, 17: Abst 1431 January, 1998
227. Relationships between patients’ pretreatment expectations and post chemotherapy experiences. Taylor AE, Olver IN, Eden J, McCaul K, Roder D Proc Am Soc Clin Oncol 1998. 17, Abs 167. January, 1998
228. An open label, non-comparative, multicentre, phase II study of Tomudex (ZD1694) in locally advanced or metastatic cancer of the head and neck Zalcberg J, Clarke S, Olver I, Rischin D, Mitchell P, Dalley D, Green M, Egan Davidson YE Proc COSA 1998, Abs 90 January, 1998
229. The Utility of Serum Hepatocyte Growth Factor (HGF) As a Marker for Breast Cancer. R Chacko, IN Olver, R Couper, J Couper, G Gill Proc COSA 1998, Abs 34. January, 1998
230. Orphan Drugs Drug Information Beyond 2000. Society of Hospital Pharmacists of Australia. Adelaide November, 1997
231. Conquering the Crab Oncology component Westmead Hospital Education Week, Sydney August, 1997
232. Adjuvant Treatment in Colonic Cancer Colorectal Surgical Society of Australia Meeting May, 1997
233. Is death ever preferable to life? ISOPP V conference, Sydney April, 1997
234. Taxol and Hexalen Combinations in Lung Cancer 5 HT3 receptor antagonists in anti-emetic therapy The Second Australian/Japanese Workshop on Cancer Research - Tokyo Japan February, 1997
235. How Often an Orphan? Royal North Shore Hospital Sydney February, 1997
236. Changes in immunological function during chemotherapy for small cell lung cancer Olver IN, Ferrante A Proc Am Soc Clin Oncol 1997, 16: Abs 1587 January, 1997
237. Breast carcinoma express functional receptors for GM-CSF Atkins G, Sun Q, Woodcock J, Faull R, To LB, Olver I 1st Electronic Lorne Cancer Conference January, 1997
238. Taxol (paclitaxel) alone is equivalent to CMFP combination chemotherapy as frontline treatment in metastatic breast cancer Bishop JF, Dewar J, Tattersall J, Smith J, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Toner G, Stephenson J, Canetta R. Proc Am Soc Clin Oncol 1997, 16: Abs 538 January, 1997
239. Impact on immunological function of chemotherapy for small cell lung cancer Olver I, Ferrante A 24th Ann Scientific Meeting January, 1997
240. Is Death Ever Preferable to Life? Grand Round, Alice Springs Hospital, NT December, 1996
241. New Drug Trials in Australia HSA/MOGA/SABT Scientific Meeting, Adelaide SA October, 1996
242. Defending a highest value of life ethic in medicine HSA/MOGA/ASBT Scientific Meeting. Adelaide SA. October, 1996
243. Physicians view of ethics in clinical trial design and conduct of studies Association for Clinical and Regulatory Scientists to the Pharmaceutical Industry (ARCS), Inaugural Clinical Conference, Sydney. July, 1996
244. Tropisetron Symposium, Chedu Island, Korea June, 1996
245. Paclitaxel Fauldings Symposium, Beijing and Shanghai, China March, 1996
246. Chemotherapy in the management of hormone refractory disease Prostate Cancer Symposium, Repatriation General Hospital, Daw Park. February, 1996
247. A phase I study of paclitaxel and altretamine in ovarian cancer relapsing after cisplatin Olver IN, Davy M. Proc COSA 23rd Ann Scientific Meeting 1996 Abs 118. January, 1996
248. Mature data from a large international randomised trial confirm significant activity for “Tomudex” (Raltitrexed), a new thymidylate synthase inhibitor in advanced colorectal cancer (ACC) Harper P, Cunningham D, Zalcberg J, Rath U, Olver IN, Van Cutsem E, Kerr D, Svensson C, Seitz JF, Perez Manga G, Rugg T. ESSO January, 1996
249. A phase III study of conventional and accelerated radiotherapy (RT) with and without carboplatin in unresectable non small cell lung cancer (NSCLC) Ball D, Bishop J, Smith J, O’Brien P, Davis S, Olver I, Walker Q, Ryan G, Joseph D. ESTRO January, 1996
250. A randomised phase III study of taxol (paclitaxel) vs CMFP in untreated patients with metastatic breast cancer Bishop JF, Dewar J, Tattersall MH, Smith J, Olver I, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Toner G, Stephenson J. Proc Am Soc Clin Oncol 1996, 15: Abs 107. January, 1996
251. Phase I study of two schedules of taxol (T) and etoposide (E) in patients (PTS) with small cell (SCLC) or non-small cell (NSCLC) lung cancer. Boyer M, Olver I, Millward M, Zalcberg J, Richardson G, McKeage M, Joughin J. Proc Am Soc Clin Oncol. 1996, 15: Abs 1177. January, 1996
252. A phase I study of paclitaxel and altretamine in ovarian cancer relapsing after cisplatin Olver IN, Davy M Proc Am Soc Clin Oncol 1996, 15: Abs 822. January, 1996
253. Modulated 5-FU: Female gender and increasing age are associated with significantly more grade 3 or 4 leucopenia and mucositis. Zalcberg J, Cunningham D, Rath U, Olver I, Kerr D, van Cutsem E, Svensson C, Seitz JF, Harper P, Seymour L. Proc Am Soc Clin Oncol 1996, 15: Abs 447. January, 1996
254. Final results and survival data of a large randomised trial of “Tomudex” in advanced colorectal cancer (ACC) confirm comparable efficacy to 5-fluortouracil plus leucovorin (5FU+LV). Seitz JF, Cunningham D, Rath U, Olver IN, Van Cutsem E, Kerr D, Svensson C, Perez Manga G, Harper P, Zalcberg J, Lowery K, Azab M Proc Am Soc Clin Oncol 1996, 15: Abs 446 January, 1996
255. Breast carcinoma cell lines express receptors for GM-CSF. Leavesley D, Faull R, To LB, Olver I, Atkins G Mol Biol Cell 7(suppl):245a, 1996 January, 1996
256. The Ethics of Telemedicine Management Search Conference on Telemedicine, South Australian Health Commission December, 1995
257. Clinical Management - a practical perspective Royal Australian College of Medical Administrators Annual Meeting, Adelaide SA . September, 1995
258. The Management of Metastatic Disease: Who Decides? Cancer Ninety-Five, an International Scientific Symposium, Townsville, Australia August, 1995
259. Testicular Cancer - A Paradigm Cancer Ninety-Five, an International Scientific Symposium, Townsville, Australia August, 1995
260. Biological Response Modifiers and Cell Support Strategies Cancer Ninety-Five, an International Scientific Symposium, Townsville, Australia August, 1995
261. MOG New Drugs Group Proposal Medical Oncology Group Midyear Meeting, Cradle Mountain, Tasmania July, 1995
262. Ethical Hypothetical, Reduced resources, increased demands - a challenge to equity Medical Oncology Group Midyear Meeting, Cradle Mountain, Tasmania July, 1995
263. An open label multicentre study of tropisetron for acute and delayed cisplatin-induced emesis Olver IN, Craft PS, Clingan PR, Kearsley JH, Planner RS, van Hazel GA, Bell DR, Adena MR, Hall BE, Pearson LL XXII Ann Congress of Korean Cancer Association January, 1995
264. Radiotherapy with and without 5-fluorouracil (5-FU) as palliation for non-small cell lung cancer (NSCLC). Ball D, Smith J, Bishop J, Olver I, Davis S, Millward M, O’Brien P, Bernshaw D, Ryan G. Proc COSA Midyear meeting 1995 January, 1995
265. Tomudex (ZD1694) has a higher response rate and significantly less life threatening toxicity than 5-flurouracil (5FU) and leucovorin (LV) in advanced colorectal cancer (CRC): First results of a large international phase III study Cunningham D, Zalcberg J, Rath U, Olver I, Kerr D, Van Cutsem E, Svensson C, Seitz JF, Harper P, Seymour L, Azab M. Can J Infectious Dis 1995, 6 (suppl C): 209C January, 1995
266. Tomudex (ZD1694) has superior response and toxicity profiles compared to 5-fluorouracil and leucovorin (5-FU-LV) in advanced colorectal cancer (CRC): first results of a large international phase III study Kerr D, Cunningham D, Zalcberg J, Rath U, Olver I, van Cutsem E, Svenson C, Seitz JF, Harper P, Lowery R Br J Cancer 1995, 72 January, 1995
267. A phase I study of prolonged ambulatory infusion carboplatin with oral etoposide showing activity in prostate cancer Olver IN, Goulding J, Stephenson J, Joughin J. Proc Am Soc Clin Oncol 1995, 14: Abs 677. January, 1995
268. Casemix: a bioethical discussion Olver IN, Long L, Halbert K Australian Bioethics Association 4th National Conference January, 1995
269. Preliminary results of a phase II study of combined modality therapy in primary CNS lymphoma: Trans-Tasman Radiation Oncology Group O,Brien P, Roos, Walker Q, Barton M, Olver I. Royal Australasian College of Radiologists Scientific Meeting January, 1995
270. Australian multicentre phase II trial of paclitaxel in previously treated patients with metastatic breast cancer (MBC). Michael M, Bishop JF, Toner GC, Smith JG, Levi JA, Zalcberg J, Friedlander M, Olver IN Proc COSA 22nd Ann Scientific Meeting January, 1995
271. Pamidronate disodium (Aredia) reduces skeletal related complications (SRE) in patients with breast cancer (BC) and osteolytic bone metastases who receive concurrent chemotherapy Bell R, Olver I, Stewart J, Wheeler H, Kennedy I, Heffernan M, Seaman J, Knight R, Reitsma D 22nd Ann Scientific Meeting January, 1995
272. Tomudex (ZD1694) has a superior response rate and less toxicity than 5-fluorouracil and leucovorin (5-FU-LV) in advanced colorectal cancer (CRC): results of a large international phase III study Clarke S, Olver I, Cunningham D, Zalcberg J, Seymour L, Azab M 22nd Ann Scientific Meeting January, 1995
273. An open label multicentre study of tropisetron for acute and delayed cisplatin induced emesis Olver IN, Craft P, Clingan P, Kearsley J, Planner R, van Hazel G, Bell D, Adena M, Hall B, Pearson L 22nd Ann Scientific Meeting January, 1995
274. The management of cytotoxic drug extravasation Clinical Oncological Society of Australia, 21st Annual Scientific Meeting, Adelaide SA November, 1994
275. Antiemetic study methodology: recommendations for future studies Round Table Emesis Conference, Marlow, England October, 1994
276. Colonic Carcinoma-Oncology Viewpoint Royal Australasian College of Surgeons, Section of Colon and Rectal Surgery, Spring Continuing Education Meeting, McLaren Vale, SA September, 1994
277. Australian Clinical Trials Northern Territory Anticancer Foundation guest lecturer for National Breast Cancer Day. Darwin September, 1994
278. Surgery combined with chemotherapy-when is it indicated Seminars in Operative Surgery for 1994. Techniques in Oncological Surgery. Adelaide 1994 August, 1994
279. Potential Uses Of Hospital Based Cancer Registries And Their Limitations National Conference Hospital‑Based Cancer Registries July, 1994
280. Assessing the impact of a written information and consent form onpatients receiving cytotoxic chemotherapy Aust Bioethics Assoc 3rd National Conf. Abstracts 1994, 57. April, 1994
281. Acute morbidity and response rate in advanced head and neck cancer treated by concurrent chemo and radiotherapy and altered fractionation radiotherapy. Narayan K, Hughes P, Olver I. Second World Congress on Laryngeal Cancer February, 1994
282. The impact of written informed consent procedures on patients receiving chemotherapy Olver IN, Turrell S, Buchanan L, Olszewski N, Laidlaw C, Willson K, Poulton G Proc COSA 1994, 92. January, 1994
283. The response of non small cell lung cancer to palliative radiotherapy is enhanced by the concurrent administration of 5 fluorouracil. Ball D, Olver IN, Bishop JF, Davis S, Smith J, Hayes AM, Bernshaw D Lung Cancer 1994, 10 Suppl 1, S334 January, 1994
284. A phase III randomized study of concurrent radical accelerated radiotherapy and carboplatin in inoperable non‑small cell lung cancer Bishop JF, Ball D, Smith J, Hayes AM, Crennan E, Davis S, Olver IN, O’Brien P, Joseph D Lung Cancer 1994, 10 Suppl 1, 335 January, 1994
285. Palliative radiotherapy (RT) with and without concurrent 5 fluorouracil (5FU) in the treatment of non-small cell lung cancer (NSCLC): results of a phase III trial. Ball D, Bishop J, Smith J, Olver I, Davis S, O’Brien P, Bernshaw D. 7th World Conf on Lung Cancer. January, 1994
286. A randomised trial of palliative radiotherapy and concurrent 5-Fluorouracil in advanced non-small cell lung cancer Ball D, Bishop J, Davis S, Ryan G, Bernshaw D, Crennan E, Smith J, Olver I, O’Brien P Prog 45th Ann Gen and Scientific Meeting, Royal Australasian College of Radiologists January, 1994
287. Are consent forms for anticancer trials adequate for informing patients? Olver IN, Buchanan L, Laidlaw C, Poulton G 19th ESMO Conf January, 1994
288. Multiple high dose chemotherapy and haemopoietic rescue for poor prognosis breast cancer To B, Basser R, Green M, Olver I, Szer J, Malycha P, Gill G, Carter N, Ward G, Collins J, Russell I, Fox R, Sheridan W, Juttner C Proc COSA. 1994, 41 January, 1994
289. Stage III breast cancer at RAH Kolias J, Gill PG, Olver I, Yeoh E Proc COSA 1994, 42 January, 1994
290. A preliminary analysis of the first 1000 patients accrued to the medical oncology database Olszewski N, Goulding J, Olver IN, Tilley C, Casarin A Proc COSA 1994, 117. January, 1994
291. Australasian multicentre phase II study of Taxol in relapsed ovarian cancer Phillips KA, Friedlander M, Olver I, Evans B, McCrystal M, Fitzharris B, Joughin J, Bishop J. Proc COSA 1994, 99 January, 1994
292. The management of cytotoxic drug extravasation Olver IN Proc COSA 1994, 60 January, 1994
293. Future Directions In Palliative Care: Playing In The Team National Hospice And Palliative Conference, Melbourne, 1993. October, 1993
294. Can We Ever Rationally Choose Death? Advanced Bioethics Course, Ethical and Legal Issues in Medical End of Life Decisions. Victoria August, 1993
295. Palliative Chemotherapy Palliative Care Education Program, Repatriation General Hospital, Hobart June, 1993
296. New anti‑cancer drug studies in Australia Stuart‑Harris R, Olver IN EORTC Early Drug Development Meeting Rotterdam June, 1993
297. Chemotherapy For Hepatic Metastases In Colorectal Cancer What, When, How?” Annual Scientific Congress, Royal Australian College of Surgeons, Adelaide, 1993 May, 1993
298. Chemotherapy for malignant glioma Olver IN Scientific Prog. RACS Annual Scientific Congress May, 1993
299. Chemotherapy for hepatic metastases in colorectal cancer Olver IN Scientific Prog. RACS Annual Scientific Congress May, 1993
300. Toxicity of concurrent radical accelerated radiotherapy and carboplatin in a randomized trial in inoperable non small cell lung cancer Bishop JF, Ball DL, Smith J, Hayes AM, Crennan E, Davis S, Olver IN, Toner J, O’Brien P, Joseph D Proc Am Assoc Canc Res, 1993, 34: 1225 January, 1993
301. Accelerated radiotherapy a comparison of two dose schedules. Hughes P, Narayan K, Olver IN Proc COSA, 1993: 39 January, 1993
302. Future directions in palliative care: playing in the team Olver IN Proc National Hospice and Palliative Care Conference January, 1993
303. A phase I study in colon cancer of modulating prolonged ambulatory infusion 5 fluorouracil with interferon Olver IN, Goulding J Proc COSA, 1993: 18 January, 1993
304. Sequential phase I studies of modulating prolonged infusion 5 fluorouracil (5 FU) with folinic acid (FA) and alpha interferon (IFN). Olver IN Eur J Cancer 29A Suppl 6: Abs 654. January, 1993
305. Late effects and survival after simultaneous continuous 5 fluorouracil (5 FU) and radiation in head and neck cancer. Olver IN, Hughes P, Smith J, Narayan K, Bishop J Proc Am soc Clin Oncol, 1993, 12: 890 January, 1993
306. Randomized, placebo controlled trial of filgrastim (r metHuG CSF) in patients with febril neutropenia (FN) following chemotherapy (CT) Maher D, Green M, Bishop J, Stuart Harris R, Lieschke G, Wolf M, Sheridan W, Kefford R, Cebon J, Olver IN, Mckendrick J, Toner G, Lieschke M, Bradstock K, Criuckshank S, Hoffman E, Fox R, Morstyn G Proc Am Soc Clin Oncol, 1993, 12: 1498 January, 1993
307. Dose finding study of prolonged ambulatory infusion 5 fluorouracil (5 FU) and oral leucovorin for colorectal cancer Olver IN, Bishop J, Baxter H Proc Am Assoc Canc Res, 1993, 34: 1196 January, 1993
308. Making Informed Choices Royal Adelaide Hospital Clinical Nurse Seminar. December, 1992
309. The physicians view of informed consent The Second Leura Breast Cancer Conference, NSW November, 1992
310. Why do we need bioethics? Seminar on Ethical Issues In Cancer. South Australian Nurses Oncology Group June, 1992
311. Haemopoiesis. Invited presentation in G‑CSF A clinical Symposium and Dinner, Perth. June, 1992
312. The Ethics of Resource Allocation: A Clinical Perspective Royal Australian College of Medical Administration course “Management for Clinicians”, Adelaide May, 1992
313. Breast Cancer: New Trends In Treatment Annual Scientific Meeting, Royal Australasian College of Physicians, Adelaide May, 1992
314. A phase II trial of zeniplatin in metastatic melanoma Olver IN, Green M, Peters W, Zimet A, Toner G, Bishop J, Ketelby W, Rastogi R, Birkhofer M Proc COSA 1992, 74. January, 1992
315. Phase I clinical and pharmacological study of high dose Toremifene in post menopausal patients with advanced breast cancer Bishop JF, Murray R, Webster L, Pitt P, Stokes K, Fennessy A, Olver IN, Leber G Clinical Digest Series 1992 January, 1992
316. Prognostic value of Quality of life (QL) scores in a clinical trial of dacarbazine (DTIC) with or without interferon alpha2a (IFN) in patients with metastatic malignant melanoma (MMM) Coates A, Thomson D, McLeod G, Hersey P, Gill P, Olver IN, Kefford R, Lowenthal R, Beadle G, Walpole E. Proc COSA 1992, 73 January, 1992
317. Registration database designed to estimate accrual to clinical trials Goulding J, Olszewski N, Olver IN, Abdi EA, Stefanou G Proc COSA 1992, 15 January, 1992
318. A phase III randomized study of concurrent radical accelerated radiotherapy (RT) and carboplatin in inoperable non‑small cell lung cancer (NSCLC). Bishop JF, Ball DL, Smith J, Hayes AM, Crennan E, Davis S, Olver IN, O’Brien P, Joseph D Second IASLC Workshop on Combined Modalities in Lung Cancer January, 1992
319. The response of non-small cell lung cancer to palliative radiotherapy is enhanced by the concurrent administration of 5 Fluorouracil. Ball D, Olver IN, Bishop J, Davis S, Smith J, Hayes AM, Bernshaw D. Second IASLC Workshop on Combined Modalities in Lung Cancer January, 1992
320. A phase I study with pharmacokinetics of prolonged ambulatory infusion carboplatin Webster L, Olver IN, Bishop J, Stokes K, Toner G. Proc Amer Assoc Canc Res. 1992, 33: 3208. January, 1992
321. Oral methotrexate for superficial transitional cell carcinoma. Olver IN, Sandeman T, Laidlaw C, Zimet A, Bishop J, Abdi E Proc Amer Assoc Canc Res 1992, 33: 1314 January, 1992
322. Escalation of dose intensity of single agent epirubicin with granulocyte‑macrophage colony stimulating factor (GM‑CSF). Toner GC, Bishop JF, Fennessy A, Woollet A, Olver IN, Zimet A Proc Am Soc Clin Oncol 1992, 11: 1459. January, 1992
323. Interferon alpha 2a (IFN) does not improve response or survival when added to dacarbazine (DTIC) in metastatic melanoma: Results of a multi institutional Australian randomised trial QMP8704. Thomson D, Adena M, McLeod GRC, Hersey P, Gill P, Coates A, Olver IN, Kefford R, Lowenthal R, Beadle G, Walpole E, Boland K, Kingston D Proc Am Soc Clin Oncol 1992 11: 1177 January, 1992
324. A pilot phase II study of zeniplatin in metastatic melanoma. Olver IN, Green M, Peters W, Zimet A, Toner G, Bishop J, Ketelbey W, Rastogi R, Birkhofer M 7th NCI‑EORTC Symposium on New Drugs in Cancer Therapy January, 1992
325. Ethical Aspects of Breast Cancer Management Clinical Oncological Society of Australia Annual Scientific Meeting, Sydney. December, 1991
326. Methodology in Antiemetic Trials ECCO VI Satellite Symposium on Zofran. Florence Italy October, 1991
327. Methodology in anti‑emetic trials Olver IN Ondansetron Satellite Symposium Abstract Book, Florence, Italy, Oct 1991: 14 16 October, 1991
328. Hyopothetical: Ethical Issues At The End Of Life Care of the Dying and Cancer Pain Relief, Trawalla, Victoria September, 1991
329. Intravesical and Oral Chemotherapy for Bladder Cancer Medical Oncology Group Mid Year Meeting, Hunter Valley N.S.W. September, 1991
330. The clinical role of hospital ethics committees National Bioethics Conference Presentation Papers 1991, 25‑30.4 April, 1991
331. Does legislation safeguard rights? Discussion of the Medical Treatment Act 1988 The Australian Bioethics Association 1st Annual Conference April, 1991
332. Antiemetic Study Design: Desirable Objectives Stratification and Analyses Round Table Emesis Conference, Paris, February, 1991
333. A phase II study with pharmacokinetics of gallium nitrate in non-small cell lung cancer Proc AACR 1991, 32; 190. Proc AACR 1991, 32; 190. January, 1991
334. Ethical aspects of breast cancer management Olver IN Proc COSA, 1991: 127 January, 1991
335. Multi Institutional prospective randomised study of dacarbazine (DTIC) + alpha 2a interferon vs DTIC alone in metastatic melanoma Thompson DB, Adena M, McLeod GRC, Hersey P, Gill P, Coates A, Olver IN, Kefford R, Lowenthal R, Beadle G, Walpole E, Bickford V, Boland K, Kingston D. Proc COSA, 1991: 110 January, 1991
336. Investigational ambulatory chemotherapy Olver IN Proc COSA, 1991: 70 January, 1991
337. A randomised double blind crossover study of domperidone suppositories for outpatient control of chemotherapy induced emesis. Olver IN, Laidlaw C, Hayes AM, Matthews J, Bishop J, Wolf M, Toner G Proc COSA, 1991: 60 January, 1991
338. Phase I study of high dose toremifene (FC1157A) in post menopausal patients with advanced breast cancer Bishop JF, Murray R, Webster L, Pitt P, Olver IN, Stokes K, Fennessy A. Proc AACR 1991, 32; 182. January, 1991
339. Pharmacokinetics of gallium nitrate in cancer patients Webster LK, Olver IN, Stokes KH. Proc ASCEP 1991. January, 1991
340. A phase III randomized trial of adding concurrent 5 fluorouracil to palliative radiotherapy for non-small cell lung cancer. Olver IN, Ball D, Smith J, Davis S, Hayes AM, Bernshaw D Lung Cancer 7 (Suppl.), 1991: 164 January, 1991
341. Dose and schedule of granulocyte macrophage colony stimulating factor (GM CSF) carboplatin and etoposide in small cell lung cancer (SCLC). Bishop JF, Morstyn G, Stuart Harris R, Matthews JF, Green M, Zalcberg J, Raghavan D, Fox R, Yuen K, Olver IN, Zimet A, Kefford R Proc Am Soc Clin Oncol 1991: 240 January, 1991
342. High dose prochlorperazine: prolonged cost effective antiemesis. Olver IN, Laidlaw CR, Wolf M, Bishop JF, Smith R, Matthews JP, Buchanan L, Cooper IA. Proc Am Soc Clin Oncol 1991, 321 January, 1991
343. The Role of Chemotherapy in Oncology Oncology Pharmacy Symposium The Oncology Pharmacists Group of Victoria. Melbourne. November, 1990
344. Combined Modality Therapy in Head and Neck Cancer Combined Medical Oncology , College of Radiology Conference, Nara, Qld August, 1990
345. Thin slice compute tomography for assessment of tumours and responses to therapy Sephton RG, Ball DL, Olver IN, Liew KH, Lawson JB Br.J.Radiol. 1990, 63 (suppl) Congress: 86. January, 1990
346. Concurrent radiotherapy (RT) and continuous ambulatory infusion 5 fluorouracil in advanced head and neck cancer. Olver IN, Hughes P, Bishop JF, Hillcoat BL, Smith J. Proc Am Soc Clin Oncol 1990, 171 January, 1990
347. Concurrent radiotherapy and cisplatinum for head and neck cancer. Olver IN, Hughes P, Narayan K, Bishop J, Smith J. Proc AACR 1990, 1125 January, 1990
348. Sequential studies of cisplatinum (DDP) then ambulatory 5FU with radiation (RT) in head and neck cancer. Olver IN, Hughes PG, Bishop JF, Smith JG. J Cancer Res Clin Oncol 1990, 498. January, 1990
349. Phase I study of flavone acetic acid (FAA) with pharmacokinetics. Olver IN, Webster LK, Bishop JF Proc COSA 1990 January, 1990
350. New Directions in Cancer Treatment The Society of Hospital Pharmacists of Australia Meeting, clinical Oncology Pharmacy: Principles and Practice. Canberra November, 1989
351. Cancer Chemotherapy ‑ Useful or Useless? Monash University Medical School Annual Update Course for General Practitioners. Melbourne November, 1989
352. The Role of Chemotherapy in the Multimodality Management of Carcinoma of the Anal Canal 40th Annual General and Scientific Meeting of the Royal Australasian College of Radiologists October, 1989
353. The Clinical Use of Metal Complexes as Radiation Sensitizers Symposium on Metal Complexes in the Detection and Treatment of Cancer. Marysville, Victoria. July, 1989
354. Treatment of Advanced Breast Cancer Haemato Oncology Symposium Launceston General Hospital. June, 1989
355. Early Phase Drug Studies in Australia Medical Oncology Group Conference, New Drugs, New Directions, Canberra April, 1989
356. The clinical use of metal complexes as radiation sensitizers. Olver IN. Symposium on Metal Complexes in the Detection and Treatment of Cancer January, 1989
357. Phase II study of Gallium nitrate in patients with non small cell lung cancer. Olver IN, Sephton R, Bishop JF, Hillcoat BL, Ball D Symposium on Meta Complexes in the Detection and Treatment of Cancer January, 1989
358. Granulocyte macrophage colony stimulating factor (GM CSF) for the reduction of neutropenia with carboplatin and VP16 for small cell lung cancer Bishop J, Morstyn G, Stuart Harris R, Raghavan D, Kefford R, Lieschke G, Bonnen E, Olver IN, Green M, Rallings M, Fox R 3rd Intl Workshop on Small Cell Cancer. Elsinor, Denmark 1989. January, 1989
359. The role of patient assessments in antiemetic trials Smith RA, Matthews JP, Bishop JF, Olver IN Proc Am Soc Clin Oncol 1989, 8: 1263 January, 1989
360. Optimal scheduling of granulocyte macrophage colony stimulating factor (GM CSF) for the abrogation of chemotherapy induced neutropenia in small cell lung cancer (SCLC). Morstyn G, Stuart Harris R, Bishop J, Raghavan D, Kefford R, Lieschke G, Bonnen E, Olver IN, Green M, Rallings M, Fox R Proc Am Soc Clin Oncol 1989, 8: 850. January, 1989
361. Phase I pharmacokinetic study of doxifluridine given by five day stepped dose infusion Olver IN, Reece PA, Morris RG, Bishop JF, Guentert TW, Hill HS, Hillcoat BL Invest New Drugs 1989, 4: 379 January, 1989
362. Nitrogen Mustard, Vincristine, Procarbazine and Prednisolone for relapse after radiation in Hodgkin’s disease Olver IN Internal Medicine Digest 1989, 2: 24‑25 January, 1989
363. Chemotherapy of Melanoma Pigmented Lesion Conference, Australian College of Dermatologists Victorian faculty November, 1988
364. Should Ethics Committees Have A Clinical Role? Monash Centre for Human Bioethics A conference on the role, methods and nature of institutional Ethics Committees November, 1988
365. High Dose Prochlorperazine Royal Australasian College of Physicians Meeting May, 1988
366. Etoposide, carboplatin, cyclophosphamide and vincristine (ECCO) in previously untreated patients with small cell lung cancer Zalcberg J, Bishop JF, Kefford R, Raghavan D, Olver IN, Stuart Harris R, Friedlander M, Bull C, Ball D Lung Cancer 4 (Suppl), 1988, A103. January, 1988
367. Pharmacokinetics of flavone acetic acid as a 12 hour infusion to cancer patients Webster LK, Olver IN, Stokes KH, Hillcoat BL ASCEP 1988. January, 1988
368. Dose optimization and pharmacokinetics of prochlorperazine when used as an antiemetic with cytotoxic chemotherapy Olver IN, Webster LK, Bishop J, Clarke J, Hillcoat BL Proc COSA 1988, 87. January, 1988
369. A phase I dose finding study for intravenous prochlorperazine as an antiemetic for chemotherapy induced emesis. Olver IN, Bishop JF, Hillcoat BL, Clarke J Proc Am Soc Clin Oncol 1988, 7: 1112. January, 1988
370. A phase II stdy of VP16, carboplatin, cyclophosphamide and vincristine (ECCO) in previously untreated patients with small cell lung cancer (SCLC) Bishop JF, Raghavan D, Zalcberg J, Kefford R, Ball D, Olver IN, Yuen K, Friedlander M Proc Am Soc Clin Oncol 1988, 7: 802 January, 1988
371. A prospective trial of topical dimethyl sulphoxide for treating anthracycline extavasation Olver IN, Aisner J, Hament A, Buchanan L, Smardon C, Kaplan RS Proc Am Soc Clin Oncol 1988, 7: 1082. January, 1988
372. Advanced Head and Neck Cancer ‑ New Drug Trials in Australia Annual Scientific Meeting, Clinical Oncological Society of Australia, Melbourne November, 1987
373. stomach bloat in rodents a model for the emetic potential of new platinum drugs Roos IAG, Olver IN 5th Int Symp on Platinum in Cancer Chemotherapy June, 1987
374. Carboplatin ‑ The Australian Experience University of Maryland Cancer Center Grand Rounds May, 1987
375. Cyclophosphamide, methotrexate, 5 fluorouracil and prednisolone rapidly alternating with adriamycin and vincristine (CMFP/AV) in previously untreated patients with advanced breast cancer. Bishop JF, Olver IN, Rischin D, Zimet A, Jeal PN. Proc COSA 1987, 14: 41. January, 1987
376. Carboplatin and VP16 213 with radiotherapy as initial treatment for patients with small cell cancer. Olver IN, Raghavan D, Bishop J, Morstyn G, Kefford R, Stuart Harris R, Aroney R, Ball D, Fox R, Hillcoat B Invest New Drugs 1987, 5: 62. January, 1987
377. Etoposide, carboplatin, cyclophosphamide and vincristine (ECCO) in previously untreated patients with small cell lung cancer Bishop JF, Kefford R, Raghavan G, Zalcberg J, Olver IN, Stuart Harris R, Friedlander M, Bull C, Ball D Proc COSA 1987, 14: 88 January, 1987
378. Advanced head and neck cancer ‑ new drug trials in Australia Olver IN Proc COSA 1987, 14: 85 January, 1987
379. Development of a murine model for testing the emetic potential of new drugs and efficacy of antiemetics. Olver IN, Roos IAG, Hillcoat BL Proc COSA 1987, 14: 85 January, 1987
380. Tracking chemotherapy induced nausea Olver IN Cope Magazine January, 1987
381. Relationship between myelosuppression and disposition of the new anticancer drug trimetrexate Morris RG, Reece PA, Bishop JF, Olver IN, Raghavan D Xth Int Conf of Pharmacol, Sydney 1987. January, 1987
382. Small bowel obstruction as a late complication of the treatment of Hodgkin’s disease. Pearl P, Olver IN, Aisner J Proc Am Soc Clin Oncol 1987, 23: 487 January, 1987
383. The effect of escalating doses of prochlorperazine in cisplatinum (DDP) induced gastric distension in mice Olver IN, Roos IA, Thomas K, Hillcoat BL Proc AACR 1987, 1705 January, 1987
384. Carboplatin (CBDCA) and continuous infusion 5 fluorouracil (5FU) in advanced head and neck cancer Olver IN, Bishop JS, Woods R, Aroney R, Hughes P, Page J, Hillcoat BL Proc Am Soc Clin Oncol 1987, 23: 487. January, 1987
385. Disposition of a new methotrexate analogue, trimetrexate given by 5 day infusion to patients. Morris RG, Reece PA, Bishop J, Olver IN, Raghavan D Third World Conference on Clinical Pharmacology and Therapeutics, Stockholm, Sweden July, 1986
386. Phase I study of trimetrexate (TMTX) as a 5 day continuous infusion Olver IN, Bishop J, Raghavan D, Reece PA, Morris R Proc COSA 1986, 13: 137 January, 1986
387. Disposition of a new methotrexate analogue, trimetrexate given by five day continuous infusion to patients Morris RG, Reece PA, Bishop JF, Olver IN, Raghavan D Acta Pharmacologica et Toxiologica 1986, Suppl V, 1545 January, 1986
388. Carboplatin and VP16 with radiotherapy as initial treatment for patients with small cell lung cancer Ball D, Raghavan D, Bishop JF, Morstyn G, Kefford R, Stuart Harris R, Aroney R, Olver IN, Fox R, Hillcoat B Proceedings of Royal Australasian College of Radiologists, Singapore January, 1986
389. Phase II trial of N methylformamide (NMF) in patients with unresectable or recurrent renal cell carcinoma Silva H, Abrams J, Olver IN, Eisenberger M, Tchekmedyian NS, Leavitt R, Van Echo D, Aisner J. Proc Am Soc Clin Oncol 1986, 22: 416 January, 1986
390. Phase I pharmacokinetic study of the methotrexate analogue, trimetrexate, in patients with advanced cancer. Morris RG, Reece PA, Bishop JF, Olver IN, Raghavan D Proc COSA 1986, 13: 30 January, 1986
391. Carboplatin (CBDCA,JM8) VP16‑213 combination chemotherapy in previously untreated patients with small cell lung cancer Stuart Harris R, Bishop JF, Raghavan D, Morstyn G, Ball D, Hillcoat B, Fox R Kefford R, Olver IN Proc Am Soc Clin Oncol 1986, 22: 733 January, 1986
392. Carboplatin (CBDCA, JM8) VP16‑213 in previously untreated patients with small cell lung cancer (SCLC). Bishop JF, Stuart Harris R, Raghavan D, Olver IN, Ball D, Morstyn G, Aroney R, Hillcoat B, Fox R, Kefford R. Prog Thoracic Society of Australia Annual Scientific Meeting 1986, 2. January, 1986
393. Hodgkin’s disease treated with nitrogen mustard, vincristine, procarbazine and prednisolone (MOPP) long term follow up. Wolf MM, Olver IN, Ding JC, Cooper IA, Cruickshank D, Worotniuk D Proc COSA 1985, 12: 94. January, 1985
394. Lorazepam: A double blind randomized cross over study of a new antiemetic in patients receiving cytotoxic chemotherapy. Bishop JF, Olver IN, Wolf MM Year Book of Cancer 1984, Hickey RC Ed. 1985, 287 288. January, 1985
395. Phase II trial of carboplatin (CBDCA) in non small cell lung cancer Olver IN, Donehower RC, Van Echo DA, Ettinger DS, Aisner J. Proc Am Soc Clin Oncol 1985, 4: C709, 182. January, 1985
396. A review of the design and evaluation of antiemetic studies. Olver IN, Simon R, Aisner J. Proc COSA 1985, 12: 80. January, 1985
397. Lorazepam: A randomized double blind cross over study in patients receiving Cytotoxic chemotherapy Bishop JF, Olver IN, Wolf MM, Matthews JP, Long M, Bingham J, Hillcoat BL, Cooper IA Proc COSA, 1983 January, 1983
398. Treatment of advanced MOPP resistant Hodgkin’s disease with ABVP Olver IN, Wolf MM, Bishop JF, Ding JC, Cooper IA, Matthews JP Proc COSA 1982, 97 January, 1982



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
International Annual Meeting on Supportive Care in Cancer (MASCC/ISOO 2016) International Annual Meeting on Supportive Care in Cancer (MASCC/ISOO 2016) June, 2016
International Annual Meeting on Supportive Care in Cancer (MASCC/ISOO 2015) International Annual Meeting on Supportive Care in Cancer (MASCC/ISOO 2015) June, 2015
15th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2014) 15th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2014) November, 2014
Aspirin for whom and preventing which disease? Cosa 38th Annual Scientific Meeting November, 2011

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.